Feinstein Institute for Medical Research reported on Tuesday the receipt of a grant from the National Institutes of Health (NIH) to develop and test a digital health platform to help young female cancer survivors evaluate their options for having children, make decisions and plan for the future.
This five-year, USD693,000 NIH grant was awarded to Feinstein Institute for Medical Research's assistant professor, Catherine Benedict, PhD.
The new female fertility decision tool being created by Dr Benedict and her team in the Center for Health Innovations and Outcomes Research has the potential to be a much-needed aid for the more than 400,000 young adult female cancer survivors currently living in the US, many of whom hope to achieve parenthood someday.
Through the NIH aid, Dr Benedict will develop a web-based fertility decision-making tool for female cancer survivors. The participants under the study will provide feedback and complete surveys to determine if the tool was helpful and whether it led to improved decision-making and lowered distress during the process.
Under the first phase of study, Dr Benedict will work with a development team to build a web-based decision support and planning tool based on the data that examined how young women after cancer treatment made decisions regarding future family-building and the kind of support they wish they had when making those decisions. The second phase will allow female cancer survivors to use the tool in helping them make fertility decisions.
The Feinstein Institute for Medical Research is the research arm of Northwell Health, reportedly the largest health care provider in New York.
TheraCryf advances lead addiction programme to final preclinical stage
Dizal meets primary endpoint in Phase 3 study of ZEGFROVY (sunvozertinib) monotherapy
Novartis to acquire PI3K-alpha inhibitor program from Synnovation in deal worth up to USD3bn
IBA and Telix partner to expand US radiopharmaceutical manufacturing capacity
Pfizer reports Phase 3 TALAPRO-3 results showing improved outcomes in metastatic prostate cancer
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars
Avacta opens Phase 1 trial for AVA6103 cancer therapy in US
Imfinzi approved in EU for perioperative treatment of early gastric and gastroesophageal cancers
Aditxt acquires Ignite Proteomics to enhance cancer therapy selection
NASA awards Redwire USD4m to advance drug development in microgravity
Elicera Therapeutics receives Japanese patent allowance for ELC-401 CAR T-cell candidate
Curatis and Neupharma partner to develop corticorelin for peritumoral brain edema in Japan
Citius Oncology reports positive topline results from Phase 1 clinical trial of LYMPHIR combination
GenomOncology partners with WeTrials to support CNS cancer clinical trials